Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

By M. Baum, A. Budzar, Jack Cuzick, J. Forbes, J. Houghton, J. Klijn, T. Sahmoud. The Lancet, 2002

2,022 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer (2003, methodology): “Survival data were based on 1079 first events, and the median follow-up time for the first DFS analysis was 33 months.(1) At the time of that analysis, concerns were raised over the immaturity of the data and the fact that the benefits of tamoxifen persist beyond the 5 years of active treatment.”
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. (2006, neutral): “Prostate 50 926 0 70 33 383 (66) 7041 (14) 3515 (7) 6987 (14) Breast 44 744 99 62 27 014 (60) 13 629 (30) 2029 (5) 2072 (5) Lung 45 215 45 69 6558 (15) 8775 (19) 22 486 (50) 7396 (16) Colon/rectum 32 157 50 71 10 623 (33) 12 766 (40) 6409 (20) 2359 (7) Melanoma 9930 44 55 8065 (81) 431 (4) 466 (5) 9”
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, result): “In each study, the difference in the degree of Ki67 suppression between the study arms mirrored the difference in recurrence in equivalent large adjuvant trials, Arimidex, Tamoxifen Alone or Combined (ATAC) trial and Breast International Group (BIG) 1-98 trial, respectively (18,19).”